EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 - Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLASTM Ultra Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLASTM Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) Announced pivotal results from the 209-patient FULCRUM-VT trial, which were presented in a late-breaking session at Heart Rhythm Society 2026, demonstrating a promising safety profile with only 2.4% protocol-defined Major Adverse Events and six-month results of 84% freedom from implantable cardioverter defibrillator (“ICD”) shock and a 7…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Adagio Medical Holdings, Inc
ADGMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 11, 2026, Adagio Medical Holdings, Inc. issued a press release announcing financial results for the quarter ended June 30, 2026, and providing a business update. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.…
Company context
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low temperature ablation (“ULTA”, formerly known as ULTC) technology. ULTA is designed to create large footprint, titratable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS Ventricular Ablation System, which is CE Marked, and in May 2026 the Company submitted the results of the FULCRUM-VT pivotal study to support its PMA application to the FDA for the vCLAS Ventricular Ablation System. The Company is also developing a next-generation vCLAS Ultra catheter, designed to support faster ablation procedures with a smaller and more flexible form factor than its predecessor vCLAS device.